University Of Texas Taysha Gene Therapies, Inc. Transaction History

University Of Texas

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$5.22 - $11.86 $5.99 Million - $13.6 Million	-1,147,040 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$15.82 - $21.57 $3.86 Million - $5.27 Million	-244,150 Reduced 17.55%	1,147,040 $21.4 Million
Q2 2021 Aug 06, 2021	SELL	$19.29 - $26.38 $15.2 Million - $20.8 Million	-787,810 Reduced 36.15%	1,391,190 $29.5 Million
Q1 2021 May 07, 2021	BUY	$20.3 - $31.75 $3.63 Million - $5.68 Million	179,000 Added 8.95%	2,179,000 $44.2 Million
Q3 2020 Nov 06, 2020	BUY	$22.4 - $24.47 $44.8 Million - $48.9 Million	2,000,000 New	2,000,000 $44.8 Million

112

136M

65.4K

41.7K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $81.7M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of University Of Texas, based on Form 13F filings with the SEC.

Stay updated on University Of Texas with notifications on news.